Page 925«..10 20..924925926 927..930 940..»

Category Archives: Transhuman News

Neurophth Therapeutics and Hopstem Biotechnology Announce Strategic Partnership to Develop Human Induced Pluripotent Stem Cell-Derived Therapies for…

Posted: June 2, 2021 at 5:52 am

HOUSTON and SAN DIEGO, June 1, 2021 /PRNewswire/ -- Neurophth Biotechnology Ltd., a fully-integrated genetic medicines company developing AAV-mediated gene therapies for the treatment of ocular diseases, and Hopstem Biotechnology, the leading human induced pluripotent stem cell (hiPSC) and neural differentiation technology platform company, today announced a strategic partnership aiming to provide human iPSC-derived cell therapy for ocular diseases.

The partnership leverages Neurophth's experience in global gene/cell therapy drugs development and understanding of ophthalmic diseases to complement Hopstem's expertise in GMP manufacturing and quality assurance of iPSC-derived clinical cell products to provide next-generation ocular treatments. Under the terms of agreement, Hopstem Biotechnology will receive upfront and milestone payments for the development of candidate cell product for agreed retinal degenerative disorder. Neurophth will have the option to license the candidate product and will be responsible for development and commercialization of the licensed product. In addition, Neurophth agreed to license Hopstem's iPSC reprogramming patent and GMP iPSC line with additional payments to Hopstem at different product development stages. According to the agreement, Hopstem will also share part of the product sales.

"This collaboration exemplifies Neurophth's long-term commitment to advancing the field of ophthalmic treatment as we continue to expand and progress our innovative pipeline of ocular candidates," said Bin Li, M.D., Ph.D., Founder and Chairman of Neurophth Therapeutics. "Combining the methods of stem cell technology, induced pluripotent stem cells is a promising technology that can offer an extraordinary potential for regenerative therapy, disease modeling and drug screening."

"We are very excited by this partnership with Neurophth. The human induced pluripotent stem cell (hiPSC) line we developed is made by transforming the skin of a healthy donor into stem cells that are capable of multiplying and becoming any type of cell in the human body, meeting GMP requirements. Thanks to our iPSC-derived clinical cell product manufactory and quality platform developed since 2019, we are able to speed up ocular cell product development with Neurophth, the leading ocular therapy company in the field. Together, our aim is to offer safe and effective regenerative medicine with hiPSC-derived cellsfor reversing the progression of ocular diseases and restoring vision for patients," Jing Fan, Ph.D., Founder and CEO of Hopstem Biotechnology.

"iPSCs holds the promise for treatment of retinal degenerative disorders where AAV-mediated gene therapy is unreachable," said Alvin Luk, Ph.D., M.B.A., CEO at Neurophth. "Hopstem is one of the most respected pioneers in the field of iPSC translational medicine. We are confident that their technology and expertise, combined with Neurophth's deep knowledge in ophthalmology and drug development, has the potential to unlock future generations of gene/cell therapy treatments for patients."

About Neurophth

Neurophth is China's first gene therapy company for ophthalmic diseases. Headquartered in Wuhan with subsidiaries in Shanghai, Suzhou, and US, Neurophth, a fully integrated company, is striving to discover and develop gene therapies for patients suffering from blindness and other eye diseases globally. Our validated AAV platform which has been published in Nature - Scientific Reports, Ophthalmology, and EBioMedicine, has successfully delivered proof-of-concept data with investigational gene therapies in the retina. Our most advanced investigational candidate, NR082 (NFS-01 project, rAAV2-ND4), in development for the treatment ofND4-mediated Leber hereditary optic neuropathy (LHON), has granted orphan designation by theU.S FDA and its IND has also been approved by China NMPA. The pipeline also includesND1-mediated LHON, autosomal dominant optic atrophy, optic neuroprotection (e.g., glaucoma), vascular retinopathy (e.g., diabetic macular edema and wet age-related macular degeneration), and five other preclinical candidates. Neurophth has initiated the scaling up in-house manufacturing process in single-use technologies to support future commercial demand at the Suzhou facility. To learn more about us and our growing pipeline, please visitwww.neurophth.com.

About Hopstem

Hopstem Biotechnology is one of the first few iPSC cell therapy companies in China. The company was founded in January 2017 in Hangzhou (China) and Baltimore (US) by neuroscientists and stem-cell biologists from Johns Hopkins University. Hopstem has established a world-leading neural differentiation platform as well as patented iPSC reprogramming method and high standard GMP manufactory and quality system. The mission of Hopstem is to apply these cutting-edge technologies to develop innovative cell therapies for CNS and other disorders. Our leading clinical product, hNPC01, is a human forebrain neural progenitor cell product for stroke and traumatic brain injuries, etc. Preliminary studies in rat and monkey pMCAO stroke models have suggested that majority of those transplanted hNPCs differentiated into functional neural cells and formed significant new connections with the rat neurons in distal regions. To learn more about us, please visit http://www.hopstem.com.

View original content:http://www.prnewswire.com/news-releases/neurophth-therapeutics-and-hopstem-biotechnology-announce-strategic-partnership-to-develop-human-induced-pluripotent-stem-cell-derived-therapies-for-the-treatment-of-ocular-diseases-301302715.html

SOURCE Neurophth Therapeutics, Inc.

Posted in Gene Medicine | Comments Off

Vence Bonham to be appointed acting NHGRI deputy director – National Human Genome Research Institute

Posted: at 5:52 am

On May 17, NHGRI announced plans to appoint Vence Bonham Jr., J.D. as acting deputy director. Vence, who joined NHGRI in 2003, is currently senior advisor to the NHGRI director on genomics and health disparities as well as head of the Health Disparities Unit in NHGRIs Social and Behavioral Research Branch. His appointment as acting deputy director will expand on his current roles, in which he has made major contributions to the Institutes research on diversity, inclusion, and health equity. In this new role, Vence will assume a more elevated position at the Institute, helping the NHGRI leadership advance NHGRIs mission and priorities.

The NHGRI deputy director position has been vacant since Mark Guyer, Ph.D., retired in 2014. The upcoming appointment of Vence as the NHGRI acting deputy director reflects the Institutes desire to have a leader at the highest possible level to guide programmatic activities to advance work related to diversity, inclusion, and health equity at the national level, but also lead NIH and NHGRIs efforts to address anti-racism and social justice. These are significant priority areas for NHGRI, and Vences leadership will be invaluable.

One of Vences first responsibilities as acting deputy director will be to create a new Office of Workforce Diversity and Health Equity within the NHGRI Office of the Director. The new office will work towards NHGRIs goals Vence will work closely with other NHGRI leaders to develop the offices mission and vision, establish a staffing plan, and lead efforts to recruit its first director.

Vence is familiar with NHGRIs long-standing leadership on issues related to diversity in genomics. Most recently, he led the NHGRI Genomic Workforce Diversity Working Group that established an action agenda for enhancing the diversity of the genomics workforce, which was published earlier this year. Vence and NHGRIs Director, Dr. Eric Green, also co-authored a commentary in the American Journal of Human Genetics, which described the imperative to enhance the diversity of the genomics workforce for achieving the promise of genomics. In his new role, Vence will focus on implementing this action agenda and will continue to be one of three NHGRI leaders serving on key NIH-wide committees as part of the NIH UNITE Initiative, which aims to end structural racism in biomedical research.

Vence also has a long history of starting successful initiatives at NHGRI. He established the Education and Community Involvement Branch and served as its inaugural chief. The branch thrived under his leadership, including the creation of the Smithsonian-NHGRI exhibition, Genome: Unlocking Lifes Code.

His research program focuses primarily on the social implications of new scientific knowledge, particularly in communities of color. He and his group study how genomics influences the use of the constructs of race and ethnicity in biomedical research and clinical care, as well as how genomics worsens or improves health inequities. They also study sickle cell disease, a condition that is affected by emerging curative genomic technologies and that faces significant health disparities both in the US and worldwide.

Vences appointment as the NHGRI acting deputy director is anticipated to begin in early summer.

Posted in Gene Medicine | Comments Off

Parkinsonism: Types, Causes, and More – Healthline

Posted: at 5:51 am

Many of us are familiar with Parkinsons disease, but the term parkinsonism may not be as familiar.

Parkinsonism is a term for a group of neurological conditions that cause difficulty with movement. Some of the defining symptoms of parkinsonism include:

Parkinsons disease is the most common type of parkinsonism. It makes up about 80 percent of parkinsonism cases.

Other types of parkinsonism are collectively known as atypical parkinsonian disorders or Parkinson-plus syndromes. There are many types of parkinsonism that closely mimic symptoms of Parkinsons, and diagnosis can be difficult.

In this article, we look at the different types of parkinsonism and break down the symptoms and treatment of each.

Parkinsons disease is one of many types of parkinsonism. Its caused by a loss of cells in the part of your brain that produces the neurotransmitter dopamine.

Parkinsons disease and the different types of parkinsonism progress in different ways. Some may progress more rapidly than Parkinsons disease. Others, like secondary parkinsonism, may be reversible.

The conditions also respond differently to treatments. For instance, someone who has a type of parkinsonism may not respond to the drug levodopa, which is commonly used for Parkinsons disease.

It can be hard to tell the difference between types of parkinsonism. Heres a look at some of the identified categories of parkinsonism with their typical symptoms and treatments.

Atypical parkinsonism refers to any type of parkinsonism that isnt Parkinsons disease.

Types of atypical parkinsonism include:

Multiple system atrophy is a rare and progressive disease thats characterized by abnormal deposits of protein in the nervous system. The cause is unknown, and it affects about 15,000 to 50,000 Americans.

The initial symptoms are similar to those of Parkinsons disease, but they tend to progress more quickly. They include:

Theres currently no treatment for multiple system atrophy thats known to delay the progression of the disease. Treatment involves targeting individual symptoms.

Progressive supranuclear palsy is a disorder caused by damage to parts of the brain controlling the cranial nerves. Symptoms vary between people, but the first sign is often loss of balance while walking. This condition also progresses faster than Parkinsons disease.

Other signs include:

Theres no effective treatment for progressive supranuclear palsy, and it usually doesnt respond to medication. Treatment revolves around targeting individual symptoms.

Corticobasal syndrome is a progressive neurological disorder that leads to the deterioration of certain areas of your brain. The initial sign is often trouble moving one limb. Eventually, this movement difficulty spreads to all limbs.

The onset of this syndrome is usually between ages 50 to 70. It affects roughly 5 in 100,000 people.

Symptoms vary greatly but may include:

No treatment has been found to slow the progression of corticobasal syndrome. Parkinsons drugs are generally ineffective but may help manage stiffness in some people.

Dementia with Lewy bodies is a disease that leads to deposits of alpha-synuclein proteins in the brain. These proteins are also called Lewy bodies.

Abnormal build-up of these chemicals can cause movement, behavior, mood, and cognitive changes.

More than 1 million people in the United States have Lewy body dementia. It most often occurs in adults over 50 and can progress for 2 to 20 years from its onset to death.

Movement symptoms include:

Cognitive symptoms can include:

Secondary parkinsonism is when a medical condition or medication leads to symptoms that resemble Parkinsons. The most common cause of secondary parkinsonism is a side effect of medications, also known as pseudoparkinsonism.

Some drugs can interfere with dopamine transmission in your brain and cause symptoms resembling Parkinsons.

Drugs that are known to induce parkinsonism include:

Treatment usually involves lowering the dose or ceasing use of the offending medication.

A number of underlying conditions can potentially lead to brain damage that causes parkinsonism. Some conditions include:

Treatment for parkinsonism caused by an underlying condition involves targeting the root cause and treating the symptoms.

Its thought that multiple small strokes in the part of your brain that controls movement can lead to a condition called vascular parkinsonism. Vascular parkinsonism is characterized by parkinsonism symptoms primarily in the lower limbs and an unsteady gait in the absence of tremors.

Symptoms include:

Vascular parkinsonism is typically poorly responsive to the medication levodopa. Treatment primarily focuses on treating symptoms. Physical therapy and lifestyle changes to improve cardiovascular health are often recommended.

Infantile parkinsonism-dystonia is a rare disorder thats also known as dopamine transporter deficiency syndrome. It causes a progressive decline in involuntary muscle contractions and other symptoms that resemble those of Parkinsons disease. It usually begins in infants.

Theres no cure for infantile parkinsonism-dystonia, and its caused by a mutation of the gene SLC6A3.

Symptoms of infantile parkinsonism-dystonia include:

Other symptoms can be present, like:

Treatment involves targeting individual symptoms to increase quality of life. Medications to control involuntary muscular contractions and physical therapy are also commonly used.

Juvenile parkinsonism develops before the age of 21. Juvenile parkinsonism that responds to the medication levodopa is most often caused by mutations in the genes PARK-Parkin, PARK-PINK1, or PARK-DJ1.

The symptoms of juvenile parkinsonism are the same as late-onset parkinsonism, but the onset is at a younger age.

The medication levodopa is the most common treatment. But other supportive therapies may also be used, like botulinum toxin for treating involuntary spasms, as well as deep brain stimulation and physical therapy.

No single test can diagnose parkinsonism disorders. Doctors use a combination of tests to rule out other possible conditions and make a diagnosis based on your symptoms and medical history.

For many types of parkinsonism, the exact cause isnt known. Genetic and environmental factors are both believed to play a role.

Parkinsons disease has been linked to exposure to pesticides and herbicides, as well as living close to industrial plants. Some genes are also associated with an elevated risk of developing Parkinsons.

Conditions that cause brain damage, like traumatic injuries, tumors, and exposure to certain toxins, are also potentially contributing factors to the development of parkinsonism.

The outlook of parkinsonism is highly variable depending on factors like the age of onset, the underlying cause, and your overall health. For example, late-onset Parkinsons disease tends to progress faster and cause earlier cognitive dysfunction than early-onset Parkinsons.

Parkinsonisms are progressive conditions that get worse over time. Initiating treatment shortly after symptoms begin can help increase life expectancy and improve quality of life.

For Parkinsons, the primary treatment is the medication levodopa. Treatment varies for other types of parkinsonism, but primarily involves managing symptoms.

Read this article:
Parkinsonism: Types, Causes, and More - Healthline

Posted in Gene Medicine | Comments Off

How to Coach Your Child Through Tough Situations Involving Their Psoriasis – HealthCentral.com

Posted: at 5:51 am

How to coach your child through any tricky social situation.

iStock

Pediatric psoriasis is difficult for kids to live with. Most notably because the red, scaly plaques that are the conditions calling card can not only be physically uncomfortable but draw unwanted attention. And when youre a kid, thats the last thing you wantwhich may be why adolescents with psoriasis tend to have increased levels of depression and anxiety, according to research published in Anais Brasileiros De Dermatologia. When attention is brought to an area, [a child] can feel embarrassed or ashamed, which can often lead to feelings of anxiety and isolation, says Johanna Kaplan, Ph.D., clinical psychologist and director of Washington Anxiety Center of Capitol Hill in Washington, D.C.

As a parent its difficult to see your child struggle. But you might not always know what to do or say to help. Start with these expert tips on how to deal with the four most common scenarios your child may encounter because of their psoriasis, so you can coach your child to handle themselves with strength and pride.

As a parent, its common to feel a wide range of emotions, from anger and sadness to guilt and grief, as well as a strong need to protect your child. Know that you may have to manage your Mama or Papa Bear tendencies.

Parents may feel like calling or going to the school to confront a teacher or an administrator, however, the child may not want so much attention drawn to them and so much discussion about their illness, says Elena Mikalsen, Ph.D., chief of pediatric psychology at The Childrens Hospital of San Antonio in San Antonio, TX. Its also important for the child to get at least some choice about how their illness is discussed and to feel mastery over being able to handle these discussions. With chronic illness, you often feel a lack of control, so any chance we can give kids control, we prefer to do that.

Therefore, Mikalsen encourages parents to discuss with their child whether mom or dad should intervene for them or if they prefer to handle the situation on their own. Though parents cant always control how people respond to their childs skin condition, they can model how to react in public and educate rather than get angry and defensive, she says.

Once youve talked with your child about ways you might (or might not) help, its time to prep your kid to take charge of any social situation that might arise. Heres how.

The very first thing a child of any age should be advised to do if teased about their psoriasis is to let an adult whom they trust know. This person can be a teacher, a family friend, a babysitter, or even the parent themselves. With an adults help, pre-planning comeback statements to use when they are teased by other children can help them feel more confident and less likely to be caught off-guard by bullies or insensitive students, according to Whitney Casares, M.D., a pediatrician in Portland, OR, and author of The Working Mom Blueprint: Winning at Parenting Without Losing Yourself .

Children might need help practicing their comebacks and knowing when it is an appropriate time to use them vs. when its best to rely on other friend groups or adults to protect them. Workshop the various types of teasingsuch as joking, name-calling, and bullying, so your child can decipher what route to take and when. By placing these actions on a continuum from mild to severe, it can help your child know what action to take.

For instance, if one of your childs peers jokes with them during P.E. class that their pants (worn to cover plaques) will slow them down, help them draft a comebackand it could be as simple as: the child sprinting to a finish line and saying afterwards, 'was that slow enough for you?' Pre-planning these exchanges could help build up your childs confidence. For more severe types of bullying, discuss the role teachers play.

To help alleviate the anxiety they have surrounding their condition, kids with psoriasis often choose to wear clothes that cover their flare-ups, even when its not in season (pants and long sleeves during summer). If another child comments on your childs psoriasis-concealing outfit, arm your child with the tools to make it a teaching moment about their skin condition, Dr. Casares says.

Give your child a script or talking points that they can use to briefly explain their medical diagnosis to their peers. By increasing others level of knowledge, theyll also increase others level of empathy, Dr. Casares says. When a childs peers have a deeper knowledge base around a specific disease like psoriasis, theyll be more likely to be supportive and less likely to tease or question the childs choices or needs.

The plaques caused by psoriasis are red and scaly, especially when theyre inflamed, which can draw unwanted attention to your childs skin as well as unwarranted comments from their peers. Support your child by role-playing situations that might arise, such as when other children ask innocent questions about their plaques, suggests Dr. Casares.

When children with psoriasis are able to differentiate when they are being teased vs. when others are genuinely curious about their disease, they can more easily navigate uncomfortable conversations, she says. Theyll also develop more confidence and acceptance of themselves as unique individuals. This is another situation that could become a teaching moment for your child and their peers. By educating your child more about their condition, such as its causes and symptoms, together you could create responses to the various comments they get about their plaques.

Unfortunately, this is a common scenarioone that you should definitely anticipate. The pool can be one of the most intimidating environments for children with psoriasis given large portions of skin are exposed, explains Dr. Casares. When children are discriminated against at a pooleither by exclusion from entering the water due to concerns from uninformed staff or via exclusion from insensitive peersit can be devastating and unjust.

Coach your child to speak with trusted adultssuch as a teacher, counselor, or parent of a friend, who can advocate on their behalf if other children discriminate against them. Advocacy is important in this situation so that the discrimination is not perpetuated and so that kids with psoriasis are less likely to be discriminated against in the future, Dr. Casares says.

And be proactive, suggests, Laurie Zelinger, Ph.D., a psychologist and parenting expert based in Cedarhurst, NY. Talk to summer camp and school administrators, pool management, or the head lifeguard before your child goes to the pool. This way they dont have to hear any discussions about their condition with the gatekeeper, she says. And if that isnt possible, pack a doctors note in their bag that states it is safe for them and others to swim together

Going through life with psoriasis and coping with the social fallout can be challenging for your family, but dont think you have to do it alone.

Connect your child with others who have the same condition so that they can discuss their experiences. You can do this by signing them up for a support group via the National Psoriasis Foundation, or even asking your childs dermatologist if they have a similar-aged patient who may be open and willing to connect with your child, says Marisa Garshick, M.D., a board-certified dermatologist at Medical Dermatology & Cosmetic Surgery (MDCS) in New York City. This can do wonders for your childs self-confidence, self-esteem, and mood.

Having a chronic condition during childhood can be significant and if you are noticing any changes in the mental health of your child, be sure to make your doctor aware so they can help identify and address the emotional impact of the disease, Dr. Garshick says.

By taking the steps to prepare your child for the social challenges that they may experience because of psoriasis, you are creating a foundation for understanding and for tolerating the discussions surrounding their condition. This is important because it builds up their confidence and reminds them that they are not defined by this condition alone.

Meet Our Writer

Jenn Sinrich is a Boston-based freelance writer, editor, and content strategist with a passion for all things health and beauty. She's also a proud new Mama to a one-month old daughter named Mila. In addition to Health Central, she contributes to publications including SELF, Readers Digest, Womens Health, Glam, Livestrong.com, Parents and more.

Go here to read the rest:
How to Coach Your Child Through Tough Situations Involving Their Psoriasis - HealthCentral.com

Posted in Psoriasis | Comments Off

Globel Mild To Moderate Plaque Psoriasis Market Scope and Forecast By 2021-2030 Allergan, Johnson and Johnson, Amgen, Abbvie, Eli Lilly, Dermira…

Posted: at 5:51 am

Mild To Moderate Plaque Psoriasis Market Insight, Epidemiology and Market Forecast 2030

The global Mild To Moderate Plaque Psoriasis is projected to grow from USD xx mllion in 2020 to USD xx million by 2027, at a CAGR of xx% from 2021 to 2030. The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the markets historic and forecast market growth by geography.

Key Questions Answered in Market Report:-

Get sample copy of thisreport @

https://www.infinitybusinessinsights.com/request_sample.php?id=473646

TOP Key Players @ Allergan, Johnson and Johnson, Amgen, Abbvie, Eli Lilly, Dermira Inc., Novartis, Galectin Therapeutics, Cellceutix Corporation and Biogen Inc., Bayer

The main goal for the dissemination of this information is to give a descriptive analysis of how the trends could potentially affect the upcoming future of Mild To Moderate Plaque Psoriasis market during the forecast period. This markets competitive manufactures and the upcoming manufactures are studied with their detailed research. Revenue, production, price, market share of these players is mentioned with precise information.

Global Mild To Moderate Plaque Psoriasis Market: Regional Segment Analysis

This report provides pinpoint analysis for changing competitive dynamics. It offers a forward-looking perspective on different factors driving or limiting market growth. It provides a five-year forecast assessed on the basis of how they Mild To Moderate Plaque Psoriasis Market is predicted to grow. It helps in understanding the key product segments and their future and helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments.

Key questions answered in the report include:

What will the market size and the growth rate be in 2026?

What are the key factors driving the Global Mild To Moderate Plaque Psoriasis Market?

What are the key market trends impacting the growth of the Global Mild To Moderate Plaque Psoriasis Market?

What are the challenges to market growth?

Who are the key vendors in the Global Mild To Moderate Plaque Psoriasis Market?

What are the market opportunities and threats faced by the vendors in the Global Mild To Moderate Plaque Psoriasis Market?

Trending factors influencing the market shares of the Americas, APAC, Europe, and MEA.

The report includes six parts, dealing with:

1.) Basic information;

2.) The Asia Mild To Moderate Plaque Psoriasis Market;

3.) The North American Mild To Moderate Plaque Psoriasis Market;

4.) The European Mild To Moderate Plaque Psoriasis Market;

5.) Market entry and investment feasibility;

6.) The report conclusion.

All the research report is made by using two techniques that are Primary and secondary research. There are various dynamic features of the business, like client need and feedback from the customers. Before (company name) curate any report, it has studied in-depth from all dynamic aspects such as industrial structure, application, classification, and definition.

The report focuses on some very essential points and gives a piece of full information about Revenue, production, price, and market share.

Mild To Moderate Plaque Psoriasis Market report will enlist all sections and research for each and every point without showing any indeterminate of the company.

Reasons for Buying this Report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

TABLE OF CONTENT:

1 Report Overview

2 Global Growth Trends

3 Market Share by Key Players

4 Breakdown Data by Type and Application

5 United States

6 Europe

7 China

8 Japan

9 Southeast Asia

10 India

11 Central & South America

12 International Players Profiles

13 Market Forecast 2019-2025

14 Analysts Viewpoints/Conclusions

15 Appendix

Get Up to 20% Discount on this Premium Report @

https://www.infinitybusinessinsights.com/request_sample.php?id=473646

If you have any special requirements, please let us know and we will offer you the report as you want.

About Us:

Infinity Business Insightsis a market research company that offers market and business research intelligence all around the world. We are specialized in offering the services in various industry verticals to recognize their highest-value chance, address their most analytical challenges, and alter their work.

We attain particular and niche demand of the industry while stabilize the quantum of standard with specified time and trace crucial movement at both the domestic and universal levels. The particular products and services provided by Infinity Business Insights cover vital technological, scientific and economic developments in industrial, pharmaceutical and high technology companies.

Amit J

Sales Coordinator

+1-518-300-3575

amit@infinitybusinessinsights.com

https://mobile.twitter.com/IBInsightsLLP

https://facebook.com/Infinity-Business-Insights-352172809160429

https://www.linkedin.com/company/infinity-business-insights/

Posted in Psoriasis | Comments Off

Moderate to Severe Plaque Psoriasis (ONLY CANADA DATA) Market Scope and Forecast By 2021 to 2028-Allergan, Johnson and Johnson, Amgen, Abbvie, Eli…

Posted: at 5:51 am

Moderate to Severe Plaque Psoriasis (ONLY CANADA DATA)- Market Insight, Epidemiology and Market Forecast -2030

The global market for Moderate to Severe Plaque Psoriasis (ONLY CANADA DATA) estimated at USD XX million in the year 2020, is projected to reach a revised size of USD XX million by 2027, growing at a CAGR of XX % over the analysis period 2020-2027. The report provides the analysis of the Moderate to Severe Plaque Psoriasis (ONLY CANADA DATA) market across different regions.

It aims at estimating the market size and future growth potential of this market across different segments such as form, end-use industry, and type. Furthermore, the report also includes an in-depth competitive analysis of the key players in the market along with their company profiles, SWOT analysis, recent developments, and key market strategies.

Get sample copy of thisreport @

https://www.infinitybusinessinsights.com/request_sample.php?id=473652

TOP Key Players @ Allergan, Johnson and Johnson, Amgen, Abbvie, Eli Lilly, Dermira Inc., Novartis, Galectin Therapeutics, Cellceutix Corporation and Biogen Inc., Bayer.

The main goal for the dissemination of this information is to give a descriptive analysis of how the trends could potentially affect the upcoming future of Moderate to Severe Plaque Psoriasis (ONLY CANADA DATA) market during the forecast period. This markets competitive manufactures and the upcoming manufactures are studied with their detailed research. Revenue, production, price, market share of these players is mentioned with precise information.

Global Moderate to Severe Plaque Psoriasis (ONLY CANADA DATA) Market: Regional Segment Analysis

This report provides pinpoint analysis for changing competitive dynamics. It offers a forward-looking perspective on different factors driving or limiting market growth. It provides a five-year forecast assessed on the basis of how they Moderate to Severe Plaque Psoriasis (ONLY CANADA DATA) Market is predicted to grow. It helps in understanding the key product segments and their future and helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments.

Key questions answered in the report include:

What will the market size and the growth rate be in 2026?

What are the key factors driving the Global Moderate to Severe Plaque Psoriasis (ONLY CANADA DATA) Market?

What are the key market trends impacting the growth of the Global Moderate to Severe Plaque Psoriasis (ONLY CANADA DATA) Market?

What are the challenges to market growth?

Who are the key vendors in the Global Moderate to Severe Plaque Psoriasis (ONLY CANADA DATA) Market?

What are the market opportunities and threats faced by the vendors in the Global Moderate to Severe Plaque Psoriasis (ONLY CANADA DATA) Market?

Trending factors influencing the market shares of the Americas, APAC, Europe, and MEA.

The report includes six parts, dealing with:

1.) Basic information;

2.) The Asia Moderate to Severe Plaque Psoriasis (ONLY CANADA DATA) Market;

3.) The North American Moderate to Severe Plaque Psoriasis (ONLY CANADA DATA) Market;

4.) The European Moderate to Severe Plaque Psoriasis (ONLY CANADA DATA) Market;

5.) Market entry and investment feasibility;

6.) The report conclusion.

The report focuses on some very essential points and gives a piece of full information about Revenue, production, price, and market share.

Moderate to Severe Plaque Psoriasis (ONLY CANADA DATA) Market report will enlist all sections and research for each and every point without showing any indeterminate of the company.

Reasons for Buying this Report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

TABLE OF CONTENT:

1 Report Overview

2 Global Growth Trends

3 Market Share by Key Players

4 Breakdown Data by Type and Application

5 United States

6 Europe

7 China

8 Japan

9 Southeast Asia

10 India

11 Central & South America

12 International Players Profiles

13 Market Forecast 2019-2025

14 Analysts Viewpoints/Conclusions

15 Appendix

Get Up to 20% Discount on this Premium Report @

https://www.infinitybusinessinsights.com/request_sample.php?id=473652

If you have any special requirements, please let us know and we will offer you the report as you want.

About Us:

Amit J

Sales Coordinator

+1-518-300-3575

amit@infinitybusinessinsights.com

https://mobile.twitter.com/IBInsightsLLP

https://facebook.com/Infinity-Business-Insights-352172809160429

https://www.linkedin.com/company/infinity-business-insights/

Here is the original post:
Moderate to Severe Plaque Psoriasis (ONLY CANADA DATA) Market Scope and Forecast By 2021 to 2028-Allergan, Johnson and Johnson, Amgen, Abbvie, Eli...

Posted in Psoriasis | Comments Off

Taltz Showed Consistent, Long-Term Improvement in Key Signs and Symptoms of Axial Spondyloarthritis Through Two Years in Phase 3 Study – PRNewswire

Posted: at 5:51 am

INDIANAPOLIS, June 1, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present new data from Phase 3 studies that further demonstrated the long-term efficacy and safety profile of Taltz(ixekizumab) among patients with axial spondyloarthritis (axSpA). These results are being presented at the virtual Annual European Congress of Rheumatology (EULAR), June 2-5, 2021.

AxSpA is recognized as a single disease entity, with two subtypes which are defined depending on the presence (radiographic axSpA, or r-axSpA) or absence (non-radiographic axSpA, or nr-axSpA) of defined structural damage of the sacroiliac joints on plain x-ray films as per the modified New York (mNY) criteria.

"Patients living with axial spondyloarthritis deal with a range of chronic, debilitating symptoms, including inflammatory back pain, and are in need of treatment options that can provide long-term efficacy," said Lotus Mallbris, M.D., Ph.D., vice president of immunology development at Lilly. "We are excited to present a range of new data at EULAR that demonstrate treatment with Taltz provides consistent, long-term efficacy on common signs and symptoms over time in axial spondyloarthritis."

Taltz Showed Sustained Long-Term Improvements in axSpA Through Two Years

In COAST-Y, Taltz showed consistent and sustained long-term improvements in signs and symptoms, functionality and quality of life in patients with r- and nr-axSpA. In this study, more than half of patients (56.7%) treated continuously with Taltz (80 mg every four weeks, n=157) through two years achieved Assessment of SpondyloArthritis international Society 40% response (ASAS40).

Among those treated continuously with Taltz every four weeks for two years:

The safety profile of Taltz was consistent with previously published safety data, and no new safety signals were observed after up to two years of treatment.

For methodology, see the "About the Analyses" section below. Additional results from the Phase 3 COAST-Y study were also recently published in the Annals of the Rheumatic Diseases.

Most Patients Treated with Taltz Did Not Show Bone Damage Progression of r-axSpA Up to Two Years

An analysis of two Phase 3 studies in r-axSpA (COAST-V and COAST-W) and the long-term extension trial (COAST-Y), found that 9 out of 10 patients treated with Taltz (89.6%, n=206) did not show radiographic progression for up to two years, as measured by mean change from baseline of modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) <2. Overall mean rates of progression were low among patients treated with Taltz. These results were similar among patients who were previously treated with anti-TNF therapy (88%, n= 106) and those who had not previously been treated with a biologic (91%, n=100). For methodology, see the "About the Analyses" section below.

"If left uncontrolled, individuals living with active radiographic axSpA can experience severe, chronic pain and structural damage in the spine that can lead to fusion of the spine and loss of mobility," said Walter P. Maksymowych, M.D., FRCP (C), Professor of Medicine at the University of Alberta, and Chief Medical Officer, CARE Arthritis, Edmonton, CA, and the senior author of this analysis. "Most patients treated with ixekizumab did not show structural damage progression at two years, and the degree of progression was small. In addition to known predictors, the novel finding is that attainment of remission of inflammation on MRI at one year protected from progression at two years."

Notably, Lilly will also present new analyses in axSpA and psoriatic arthritis, including the following:

More than 175,000 patients have been treated with Taltz worldwide since launch, giving healthcare providers confidence in making informed prescribing decisions for the treatment of adults with active psoriatic arthritis, active ankylosing spondylitis, active nr-axSpA and moderate to severe plaque psoriasis.

About the Analyses

INDICATIONS AND USAGE FOR TALTZ Taltz is approved for the treatment of patients 6 years of age and older with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy and for the treatment of adults with active psoriatic arthritis, active ankylosing spondylitis, or active non-radiographic axial spondyloarthritis with objective signs of inflammation.

IMPORTANT SAFETY INFORMATION FOR TALTZ

CONTRAINDICATIONSTaltz is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.

WARNINGS AND PRECAUTIONS InfectionsTaltz may increase the risk of infection. In clinical trials of adult patients with plaque psoriasis, the Taltz group had a higher rate of infections than the placebo group (27% vs 23%). A similar increase in risk of infection was seen in placebo-controlled trials of adult patients with psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and pediatric patients with plaque psoriasis. Serious infections have occurred. Instruct patients to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a serious infection develops, discontinue Taltz until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with Taltz. Do not administer to patients with active TB infection. Initiate treatment of latent TB prior to administering Taltz. Closely monitor patients receiving Taltz for signs and symptoms of active TB during and after treatment.

Hypersensitivity Serious hypersensitivity reactions, including angioedema and urticaria (each 0.1%), occurred in the Taltz group in clinical trials. Anaphylaxis, including cases leading to hospitalization, has been reported in post-marketing use with Taltz. If a serious hypersensitivity reaction occurs, discontinue Taltz immediately and initiate appropriate therapy.

Inflammatory Bowel Disease Patients treated with Taltz may be at an increased risk of inflammatory bowel disease. In clinical trials, Crohn's disease and ulcerative colitis, including exacerbations, occurred at a greater frequency in the Taltz group than the placebo group. During Taltz treatment, monitor patients for onset or exacerbations of inflammatory bowel disease and if IBD occurs, discontinue Taltz and initiate appropriate medical management.

Immunizations Prior to initiating therapy with Taltz, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with Taltz.

ADVERSE REACTIONS Most common adverse reactions (1%) associated with Taltz treatment are injection site reactions, upper respiratory tract infections, nausea, oropharingeal pain and tinea infections. Overall, the safety profiles observed in adult patients with psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and pediatric patients with plaque psoriasis were consistent with the safety profile in adult patients with plaque psoriasis, with the exception of influenza and conjunctivitis in psoriatic arthritis and conjunctivitis, influenza, and urticaria in pediatric psoriasis (also common). Adverse drug reactions in patients with radiographic axial spondyloarthritis (ankylosing spondylitis) were similar with the exception of inflammatory bowel disease (common) and rhinitis (common). In patients with non-radiographic axial spondyloarthritis, adverse events were also similar to inflammatory bowel disease (common), influenza (common) and conjunctivitis (common).

Please see full Prescribing Information and Medication Guide for Taltz. See Instructions for Use included with the device.

IX HCP ISI 07MAY2020

About TaltzTaltz is a monoclonal antibody that selectively binds with interleukin 17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor.IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses.Taltz inhibits the release of pro-inflammatory cytokines and chemokines.

About Axial SpondlyoarthritisAxial spondyloarthritis (axSpA), which includes both radiographic axSpA (r-axSpA) and non-radiographic axSpA (nr-axSpA), is a disease predominantly affecting the sacroiliac joints and the spine. Common symptoms include chronic inflammatory back pain, fatigue and stiffness.1,2,3It is estimated that 2.3 million people in the U.S. have axSpA, and approximately half of those individuals live with nr-axSpA.2,4For patients with r-axSpA, the disease is characterized by the presence of structural damage of the sacroiliac joints that appears on an X-ray, while patients with nr-axSpA do not have clearly detectable structural damage radiographically.5These two patient subsets share a similar burden of disease and similar clinical features, but approved biologic treatment options for patients with nr-axSpA are much more limited and patients are often underdiagnosed.5,6

About Lilly in ImmunologyLilly is bringing our heritage of championing groundbreaking, novel science to immunology and is driven to change what's possible for people living with autoimmune diseases. There are still significant unmet needs, as well as personal and societal costs, for people living with a variety of autoimmune diseases and our goal is to minimize the burden of disease. Lilly is investing in leading-edge clinical approaches across its immunology portfolio in hopes of transforming the autoimmune disease treatment experience. We've built a deep pipeline and are focused on advancing cutting edge science to find new treatments that offer meaningful improvements to support the people and the communities we serve.

About Eli Lilly and CompanyLilly is a global health care leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at lilly.com and lilly.com/news. P-LLY

Lilly Forward-Looking StatementThis press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Taltz (ixekizumab) as a treatment for ankylosing spondylitis, radiographic and non-radiographic axial spondylorarthritis, and psoriatric arthritis, and reflects Lilly's current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. Among other things, there can be no guarantee that Taltz will receive additional regulatory approvals or be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

1 Reveille JD, et al. Prevalence of axial spondylarthritis in the United States: Estimates from a cross-sectional survey. Arthritis Care Res. 2012;64(6):905-910.

2 Strand V, et al. Prevalence of axial spondyloarthritis in United States rheumatology practices: Assessment of SpondyloArthritis International Society criteria versus rheumatology expert clinical diagnosis. Arthritis Care Res. 2013;65(8):1299-306.

3 Kiltz U, et al. Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis? Arthritis Care Res. 2012;64(9):1415-22.

4 U.S. Census Bureau, Population Estimates Program (PEP) https://www.census.gov/quickfacts/fact/table/US# accessed on April 30, 2020.

5 Deodhar A, et al. The concept of axial spondyloarthritis: joint statement of the spondyloarthritis research and treatment network and the Assessment of SpondyloArthritis International Society in response to the US Food and Drug Administration's comments and concerns. Arth Rheum. 2014;66(10):2649-2656.

6 De Miguel Mendieta E, et al. Ann Rhuem Dis. 2018;77:1156. Abstract AB0857.

# # #

SOURCE Eli Lilly and Company

https://www.lilly.com/

Posted in Psoriasis | Comments Off

Moderate Psoriasis Market Scope and Forecast By 2021 to 2028-Merck & Co., Abb Vie Inc., Amgen Inc., Eli Lilly & company, Sun Pharmaceutical…

Posted: at 5:51 am

Moderate Psoriasis- Market Insight, Epidemiology and Market Forecast -2030

The global market for Moderate Psoriasis estimated at USD XX million in the year 2020, is projected to reach a revised size of USD XX million by 2027, growing at a CAGR of XX % over the analysis period 2020-2027. The report provides the analysis of the Moderate Psoriasis market across different regions.

Get sample copy of thisreport @

https://www.infinitybusinessinsights.com/request_sample.php?id=473649

TOP Key Players @ Merck & Co., Abb Vie Inc., Amgen Inc., Eli Lilly & company, Sun Pharmaceutical Industries Ltd, Novartis International AG, Janssen Biotech Inc., Pfizer Inc., and Boehringer Ingelheim GmbH, among others.

The main goal for the dissemination of this information is to give a descriptive analysis of how the trends could potentially affect the upcoming future of Moderate Psoriasis market during the forecast period. This markets competitive manufactures and the upcoming manufactures are studied with their detailed research. Revenue, production, price, market share of these players is mentioned with precise information.

Global Moderate Psoriasis Market: Regional Segment Analysis

This report provides pinpoint analysis for changing competitive dynamics. It offers a forward-looking perspective on different factors driving or limiting market growth. It provides a five-year forecast assessed on the basis of how they Moderate Psoriasis Market is predicted to grow. It helps in understanding the key product segments and their future and helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments.

Key questions answered in the report include:

What will the market size and the growth rate be in 2026?

What are the key factors driving the Global Moderate Psoriasis Market?

What are the key market trends impacting the growth of the Global Moderate Psoriasis Market?

What are the challenges to market growth?

Who are the key vendors in the Global Moderate Psoriasis Market?

What are the market opportunities and threats faced by the vendors in the Global Moderate Psoriasis Market?

Trending factors influencing the market shares of the Americas, APAC, Europe, and MEA.

The report includes six parts, dealing with:

1.) Basic information;

2.) The Asia Moderate Psoriasis Market;

3.) The North American Moderate Psoriasis Market;

4.) The European Moderate Psoriasis Market;

5.) Market entry and investment feasibility;

6.) The report conclusion.

The report focuses on some very essential points and gives a piece of full information about Revenue, production, price, and market share.

Moderate Psoriasis Market report will enlist all sections and research for each and every point without showing any indeterminate of the company.

Reasons for Buying this Report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

TABLE OF CONTENT:

1 Report Overview

2 Global Growth Trends

3 Market Share by Key Players

4 Breakdown Data by Type and Application

5 United States

6 Europe

7 China

8 Japan

9 Southeast Asia

10 India

11 Central & South America

12 International Players Profiles

13 Market Forecast 2019-2025

14 Analysts Viewpoints/Conclusions

15 Appendix

Get Up to 20% Discount on this Premium Report @

https://www.infinitybusinessinsights.com/request_sample.php?id=473649

If you have any special requirements, please let us know and we will offer you the report as you want.

About Us:

Amit J

Sales Coordinator

+1-518-300-3575

amit@infinitybusinessinsights.com

https://mobile.twitter.com/IBInsightsLLP

https://facebook.com/Infinity-Business-Insights-352172809160429

https://www.linkedin.com/company/infinity-business-insights/

The rest is here:
Moderate Psoriasis Market Scope and Forecast By 2021 to 2028-Merck & Co., Abb Vie Inc., Amgen Inc., Eli Lilly & company, Sun Pharmaceutical...

Posted in Psoriasis | Comments Off

SkinBioTherapeutics "delighted" with psoriasis study results, with 76% reporting less itchy skin – Proactive Investors UK

Posted: at 5:51 am

() Stuart Ashman joins Proactive London to discuss results from a study of people suffering from psoriasis that received its immune system-modulating food supplement delivering results that exceeded expectations.

In all 91 people with the condition completed the 56-day self-managed consumer study with 76% of the group reporting their skin felt less itchy, and 75% saying it appeared less red.

Ashman says the findings from the assessment of AxisBiotix-Ps, developed in collaboration with partner Winclove Probiotics, will pave the way for a commercial launch of the product in the fourth quarter.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

See the original post:
SkinBioTherapeutics "delighted" with psoriasis study results, with 76% reporting less itchy skin - Proactive Investors UK

Posted in Psoriasis | Comments Off

Psoriasis Therapeutics Market Research Report by Molecule, by Route of Administration, by Dosage Forms, by Mechanism of Action – Global Forecast to…

Posted: at 5:51 am

Psoriasis Therapeutics Market Research Report by Molecule (Biologics and Small Molecules), by Route of Administration (Oral, Parenteral, and Topical), by Dosage Forms, by Mechanism of Action - Global Forecast to 2025 - Cumulative Impact of COVID-19

New York, May 28, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Psoriasis Therapeutics Market Research Report by Molecule, by Route of Administration, by Dosage Forms, by Mechanism of Action - Global Forecast to 2025 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p05911318/?utm_source=GNW

Market Statistics:The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.

1. The Global Psoriasis Therapeutics Market is expected to grow from USD 16,490.57 Million in 2020 to USD 25,080.12 Million by the end of 2025.2. The Global Psoriasis Therapeutics Market is expected to grow from EUR 14,459.24 Million in 2020 to EUR 21,990.72 Million by the end of 2025.3. The Global Psoriasis Therapeutics Market is expected to grow from GBP 12,854.30 Million in 2020 to GBP 19,549.80 Million by the end of 2025.4. The Global Psoriasis Therapeutics Market is expected to grow from JPY 1,759,961.98 Million in 2020 to JPY 2,676,684.84 Million by the end of 2025.5. The Global Psoriasis Therapeutics Market is expected to grow from AUD 23,946.50 Million in 2020 to AUD 36,419.67 Million by the end of 2025.

Market Segmentation & Coverage:This research report categorizes the Psoriasis Therapeutics to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Molecule, the Psoriasis Therapeutics Market studied across Biologics and Small Molecules.

Based on Route of Administration, the Psoriasis Therapeutics Market studied across Oral, Parenteral, and Topical.

Based on Dosage Forms, the Psoriasis Therapeutics Market studied across Liquid, Semi-solid, and Solid.

Based on Mechanism of Action, the Psoriasis Therapeutics Market studied across IL blocker, PDE4 Inhibitors, and TNF Inhibitors.

Based on Geography, the Psoriasis Therapeutics Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles:The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Psoriasis Therapeutics Market including AbbVie Inc., Amgen, Inc., AstraZeneca, Celgene Corporation, Eli Lilly and Company, Johnson & Johnson, and Novartis AG.

Cumulative Impact of COVID-19:COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

FPNV Positioning Matrix:The FPNV Positioning Matrix evaluates and categorizes the vendors in the Psoriasis Therapeutics Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window:The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on the market offered by the key players2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as:1. What is the market size and forecast of the Global Psoriasis Therapeutics Market?2. What are the inhibiting factors and impact of COVID-19 shaping the Global Psoriasis Therapeutics Market during the forecast period?3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Psoriasis Therapeutics Market?4. What is the competitive strategic window for opportunities in the Global Psoriasis Therapeutics Market?5. What are the technology trends and regulatory frameworks in the Global Psoriasis Therapeutics Market?6. What are the modes and strategic moves considered suitable for entering the Global Psoriasis Therapeutics Market?Read the full report: https://www.reportlinker.com/p05911318/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

See the article here:
Psoriasis Therapeutics Market Research Report by Molecule, by Route of Administration, by Dosage Forms, by Mechanism of Action - Global Forecast to...

Posted in Psoriasis | Comments Off

Page 925«..10 20..924925926 927..930 940..»

Category Archives: Transhuman News

Neurophth Therapeutics and Hopstem Biotechnology Announce Strategic Partnership to Develop Human Induced Pluripotent Stem Cell-Derived Therapies for…

Vence Bonham to be appointed acting NHGRI deputy director – National Human Genome Research Institute

Parkinsonism: Types, Causes, and More – Healthline

How to Coach Your Child Through Tough Situations Involving Their Psoriasis – HealthCentral.com

Globel Mild To Moderate Plaque Psoriasis Market Scope and Forecast By 2021-2030 Allergan, Johnson and Johnson, Amgen, Abbvie, Eli Lilly, Dermira…

Moderate to Severe Plaque Psoriasis (ONLY CANADA DATA) Market Scope and Forecast By 2021 to 2028-Allergan, Johnson and Johnson, Amgen, Abbvie, Eli…

Taltz Showed Consistent, Long-Term Improvement in Key Signs and Symptoms of Axial Spondyloarthritis Through Two Years in Phase 3 Study – PRNewswire

Moderate Psoriasis Market Scope and Forecast By 2021 to 2028-Merck & Co., Abb Vie Inc., Amgen Inc., Eli Lilly & company, Sun Pharmaceutical…

SkinBioTherapeutics "delighted" with psoriasis study results, with 76% reporting less itchy skin – Proactive Investors UK

Psoriasis Therapeutics Market Research Report by Molecule, by Route of Administration, by Dosage Forms, by Mechanism of Action – Global Forecast to…

The Prometheus League

Breaking News and Updates

Prometheism

Forbidden Fruit

The Evolutionary Perspective

Transtopia Menu

Library Updates

Library Books

Future Euvolution

Lucid Dreams from Childhood

Genetic Revolution

Speciation + Self-Directed Evolution